Psoriatic Arthritis
- Lower Persistence of Biologics Observed Among Women vs Men With PsA
- Complete Skin Clearance May Lead to Long-Term Psoriasis Management
- Factors Associated With Worse COVID-19 Outcomes Among Patients With PsA, axSpA
- Secukinumab Improves Clinical Response in Plaque Psoriasis
- Targeted Therapies Do Not Increase Cardiovascular Risk in Psoriasis
- Inhibition of PCSK9 May Prevent Psoriasis Development
- Cigarette Smoking Identified as Risk Factor for Postmenopausal Psoriasis
- Uveitis in Psoriatic Arthritis Linked to Worse Quality of Life Outcomes
- Guselkumab Well Tolerated in PsA Regardless of Prior TNFi Use
- PsA Linked to Comorbidity Burden, Ustekinumab Persistence in Psoriasis
- Brodalumab Promising for the Treatment of Psoriasis, PsA
- Preexisting Radiographic Damage Linked to Time Since PsA Diagnosis
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
MORE CLINICAL TOOLS
